indomethacin has been researched along with Pancreatic Neoplasms in 17 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells." | 3.72 | Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. ( Davis, DW; Ellis, LM; Khanbolooki, S; Lashinger, LM; McConkey, DJ; Nawrocki, S; Raut, CP; Xiong, H, 2004) |
| "Indomethacin treated Panc-1 cells were analyzed with Raman spectroscopy, quantitative polymerase chain reaction and immunofluorescence techniques after the induction of EMT with TGF-β." | 1.72 | Indomethacin prevents TGF-β-induced epithelial-to-mesenchymal transition in pancreatic cancer cells; evidence by Raman spectroscopy. ( Çamdal, A; Ciftci, Z; Inal, A; Onses, MS; Sahin, F; Sakir, M; Sezer, G; Sezer, Z, 2022) |
| "Atorvastatin was found of viability reduction IC50 value <20 µM in HCT11650µM in T47D, MCF7 and PANC1." | 1.72 | Selected Statins as Dual Antiproliferative-Antiinflammatory Compounds. ( Al-Hiari, Y; Al-Qirim, T; Alalawi, S; Arabiyat, S; Haj Hussein, B; Ikhmais, B; Kasabri, V, 2022) |
| "Indomethacin is a nonsteroidal anti-inflammatory drug, which is used for blocking the production of some natural substances that cause inflammation and decrease pain." | 1.56 | Indomethacin decreases insulin secretion by reducing KCa3.1 as a biomarker of pancreatic tumor and causes apoptotic cell death. ( Karatug Kacar, A, 2020) |
| "We identified five human pancreatic cancer cell lines that express the GLP-1R and analyzed cell growth and survival in response to GLP-1R activation." | 1.33 | Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. ( Drucker, DJ; Koehler, JA, 2006) |
| "To investigate the role of COX-2 in pancreatic cancer, we evaluated COX-2 protein expression in primary human pancreatic adenocarcinomas (n = 23) and matched normal adjacent tissue (n = 11) by immunoblot analysis." | 1.31 | Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. ( Barnard, DS; Billings, SD; Cheng, L; Crowell, PL; Heilman, DK; Lin, A; Marshall, MS; Marshall, SJ; Sweeney, CJ; Yip-Schneider, MT, 2000) |
| "Two human pancreatic cancer cell lines were treated with CCK-8 alone, CCK-8 and staurosporine, or CCK-8 and indomethacine." | 1.30 | Cholecystokinin regulates the invasiveness of human pancreatic cancer cell lines via protein kinase C pathway. ( Fujimoto, Y; Hirata, M; Inoue, H; Iwao, T; Kajiyama, G; Kariya, K; Kawasaki, Y; Matsubara, K; Morinaka, K; Sasaki, T; Tsuchida, A; Yamamoto, S, 1999) |
| "Human pancreatic cancer cells (FA-6) producing bone resorbing factor were established in culture." | 1.28 | The tumor cells (FA-6) established from a pancreatic cancer associated with humoral hypercalcemia of malignancy: a simultaneous production of parathyroid hormone-like activity and transforming growth factor activity. ( Akatsu, T; Kinoshita, T; Kosano, H; Kugai, N; Nagata, N; Shimauchi, T; Takatani, O; Ueyama, Y; Yasutomo, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Narożna, M | 1 |
| Krajka-Kuźniak, V | 1 |
| Kleszcz, R | 1 |
| Baer-Dubowska, W | 1 |
| Sezer, G | 1 |
| Onses, MS | 1 |
| Sakir, M | 1 |
| Sahin, F | 1 |
| Çamdal, A | 1 |
| Sezer, Z | 1 |
| Inal, A | 1 |
| Ciftci, Z | 1 |
| Haj Hussein, B | 1 |
| Kasabri, V | 1 |
| Al-Hiari, Y | 1 |
| Arabiyat, S | 1 |
| Ikhmais, B | 1 |
| Alalawi, S | 1 |
| Al-Qirim, T | 1 |
| Karatug Kacar, A | 1 |
| Sun, L | 1 |
| Chen, K | 1 |
| Jiang, Z | 1 |
| Chen, X | 1 |
| Ma, J | 2 |
| Ma, Q | 2 |
| Duan, W | 2 |
| Han, L | 1 |
| Peng, B | 1 |
| Li, J | 1 |
| Li, W | 1 |
| Chen, C | 1 |
| Liu, J | 1 |
| Xu, Q | 1 |
| Laporte, K | 1 |
| Li, Z | 1 |
| Wu, E | 1 |
| Gibbs, JP | 1 |
| Adeyeye, MC | 1 |
| Yang, Z | 1 |
| Shen, DD | 1 |
| Raut, CP | 1 |
| Nawrocki, S | 1 |
| Lashinger, LM | 1 |
| Davis, DW | 1 |
| Khanbolooki, S | 1 |
| Xiong, H | 1 |
| Ellis, LM | 1 |
| McConkey, DJ | 1 |
| Koehler, JA | 1 |
| Drucker, DJ | 1 |
| Luyckx, AS | 1 |
| Deliege, M | 1 |
| Jardon-Jeghers, C | 1 |
| Lefebvre, PJ | 1 |
| Fennelly, JJ | 1 |
| Cantwell, B | 1 |
| Fielding, JF | 1 |
| FitzGerald, O | 1 |
| Collins, PG | 1 |
| Buchanan, KD | 1 |
| Hirata, M | 1 |
| Tsuchida, A | 1 |
| Iwao, T | 1 |
| Sasaki, T | 1 |
| Matsubara, K | 1 |
| Yamamoto, S | 1 |
| Morinaka, K | 1 |
| Kawasaki, Y | 1 |
| Fujimoto, Y | 1 |
| Inoue, H | 1 |
| Kariya, K | 1 |
| Kajiyama, G | 1 |
| Yip-Schneider, MT | 1 |
| Barnard, DS | 1 |
| Billings, SD | 1 |
| Cheng, L | 1 |
| Heilman, DK | 1 |
| Lin, A | 1 |
| Marshall, SJ | 1 |
| Crowell, PL | 1 |
| Marshall, MS | 1 |
| Sweeney, CJ | 1 |
| Liu, B | 1 |
| Staren, ED | 1 |
| Iwamura, T | 1 |
| Appert, HE | 1 |
| Howard, JM | 1 |
| Tzanakakis, GN | 1 |
| Agarwal, KC | 1 |
| Veronikis, DK | 1 |
| Vezeridis, MP | 1 |
| Takahashi, M | 1 |
| Furukawa, F | 1 |
| Toyoda, K | 1 |
| Sato, H | 1 |
| Hasegawa, R | 1 |
| Imaida, K | 1 |
| Hayashi, Y | 1 |
| Nagata, N | 1 |
| Akatsu, T | 1 |
| Kugai, N | 1 |
| Yasutomo, Y | 1 |
| Kinoshita, T | 1 |
| Kosano, H | 1 |
| Shimauchi, T | 1 |
| Takatani, O | 1 |
| Ueyama, Y | 1 |
17 other studies available for indomethacin and Pancreatic Neoplasms
| Article | Year |
|---|---|
Indomethacin and Diclofenac Hybrids with Oleanolic Acid Oximes Modulate Key Signaling Pathways in Pancreatic Cancer Cells.
Topics: Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cyclooxygenase Inhibitors; Diclofenac; | 2022 |
Indomethacin prevents TGF-β-induced epithelial-to-mesenchymal transition in pancreatic cancer cells; evidence by Raman spectroscopy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Hu | 2022 |
Indomethacin prevents TGF-β-induced epithelial-to-mesenchymal transition in pancreatic cancer cells; evidence by Raman spectroscopy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Hu | 2022 |
Indomethacin prevents TGF-β-induced epithelial-to-mesenchymal transition in pancreatic cancer cells; evidence by Raman spectroscopy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Hu | 2022 |
Indomethacin prevents TGF-β-induced epithelial-to-mesenchymal transition in pancreatic cancer cells; evidence by Raman spectroscopy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Hu | 2022 |
Selected Statins as Dual Antiproliferative-Antiinflammatory Compounds.
Topics: Anti-Inflammatory Agents; Atorvastatin; Caco-2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2022 |
Indomethacin decreases insulin secretion by reducing KCa3.1 as a biomarker of pancreatic tumor and causes apoptotic cell death.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Indomethacin; Insulin; Insul | 2020 |
Indometacin inhibits the proliferation and activation of human pancreatic stellate cells through the downregulation of COX-2.
Topics: Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cy | 2018 |
Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of e-cadherin in pancreatic cancer cells.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Down-Regulation; Glucose; | 2013 |
Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
Topics: Adenocarcinoma; Animals; Biological Transport, Active; Brain; Cattle; Cells, Cultured; Cyclooxygenas | 2004 |
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cyclooxygena | 2004 |
Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells.
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Cholera Toxin; Chromones; Cycloheximide; | 2006 |
Insulin, prostaglandin E2 and glucagon release by human tissue incubated in vitro. Influence of indomethacin.
Topics: Adenoma, Islet Cell; Adult; Glucagon; Humans; In Vitro Techniques; Indomethacin; Insulin; Insulin Se | 1981 |
Metastatic pancreatic vipoma: a case report of clinical response following treatment with corticosteroids and actinomycin D.
Topics: Adenoma, Islet Cell; Dactinomycin; Female; Humans; Indomethacin; Liver Neoplasms; Middle Aged; Pancr | 1982 |
Cholecystokinin regulates the invasiveness of human pancreatic cancer cell lines via protein kinase C pathway.
Topics: Blotting, Western; Cholecystokinin; Collagenases; Cyclooxygenase Inhibitors; Dinoprostone; Dopamine | 1999 |
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Cell Line, Transformed; Codon; Cricetinae; Cyclooxygenase 2; Cyclooxygenase | 2000 |
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineopla | 2001 |
Effects of antiplatelet agents alone or in combinations on platelet aggregation and on liver metastases from a human pancreatic adenocarcinoma in the nude mouse.
Topics: Adenocarcinoma; Animals; Colforsin; Drug Interactions; Humans; Indomethacin; Ketoconazole; Liver Neo | 1991 |
Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinogens; Cricetinae; Female; Indometh | 1990 |
The tumor cells (FA-6) established from a pancreatic cancer associated with humoral hypercalcemia of malignancy: a simultaneous production of parathyroid hormone-like activity and transforming growth factor activity.
Topics: Animals; Biological Assay; Bone and Bones; Bone Resorption; Chromatography, Gel; Culture Media; Cycl | 1989 |